| |
GS-9148 Nucleotide Active Against Resistance
|
| |
| |
"GS-9148 retained its activity against viruses with four or more TAMs, including combinations containing the M41L and L210W mutations....Viruses carrying the K65R, K70E, L74V, or M184V mutation, as well as various combinations thereof, were fully susceptible or slightly hypersensitive to GS-9148.....GS-9148 showed a minimal loss of activity against a multidrug-resistant virus containing TAMs in combination with M184V and an insertion at T69......suggesting a less effective renal transport and possibly a lower potential for nephrotoxicity than that of acyclic nucleotide analogs. Finally, quantitative studies confirmed that despite increased cellular permeation, GS-9131 at concentrations of up to 50 µM did not cause any selective depletion of mtDNA in HepG2 cells (data not shown), an observation consistent with the low potential of GS-9148 to interfere with the replication of mtDNA."
The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09)
GS9148: A Novel Nucleotide Active Against HIV-1 Variants with Drug ...
Feb 6, 2006 ... Preliminary pre-clinical data shows GS9148 appears potent and safe, and did not show an effect on mitochondrial DNA; was effective against ...
www.natap.org/2006/CROI/CROI_02.htm
Inefficient Renal Transport of Nucleotide Reverse Transcriptase ...
GS-9148 is a novel nucleotide HIV RT inhibitor active against a variety of ... GS-9148 showed relatively inefficient transport by the renal uptake ...
www.natap.org/2008/CROI/croi_107.htm
Novel Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in ...
GS-9148 (Fig. 1) is a novel nucleotide HIV RT inhibitor with a favorable in vitro resistance profile against HIV-1 strains with clinically relevant ...
www.natap.org/2007/ICAAC/ICAAC_28.htm
Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131
Antimicrobial Agents and Chemotherapy, February 2008
Tomas Cihlar,1* Adrian S. Ray,1 Constantine G. Boojamra,1 Lijun Zhang,1 Hon Hui,1 Genevieve Laflamme,1 Jennifer E. Vela,1 Deborah Grant,1 James Chen,1 Florence Myrick,2 Kirsten L. White,1 Ying Gao,1 Kuei-Ying Lin,1 Janet L. Douglas,1 Neil T. Parkin,3 Anne Carey,1 Rowchanak Pakdaman,1 and Richard L. Mackman1
Gilead Sciences, Foster City, California,1 Gilead Sciences, Durham, North Carolina,2 Monogram Biosciences, South San Francisco, California3
"GS-9131 is an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.....The discovery of the favorable resistance profile of the previously described nucleoside phosphonate d4AP (20) was an important initial step toward the design of GS-9148.....Results from a PhenoSense analysis indicate that GS-9148 meets the target resistance profile set for the development candidate by maintaining its activity against multiple patient-derived HIV strains with the major known NRTI resistance mutations. Importantly, its profile appears to be distinct from that of the clinically approved NRTIs in that GS-9148 was the only inhibitor tested that showed no reduction in potency due to K65R, L74V, and M184V mutations, together with the minimal resistance associated with multiple TAMs
"
ABSTRACT
GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosphonic acid] is a novel ribose-modified human immunodeficiency virus type 1 (HIV-1) nucleotide reverse transcriptase (RT) inhibitor (NRTI) selected from a series of nucleoside phosphonate analogs for its favorable in vitro biological properties including (i) a low potential for mitochondrial toxicity, (ii) a minimal cytotoxicity in renal proximal tubule cells and other cell types, (iii) synergy in combination with other antiretrovirals, and (iv) a unique resistance profile against multiple NRTI-resistant HIV-1 strains. Notably, antiviral resistance analysis indicated that neither the K65R, L74V, or M184V RT mutation nor their combinations had any effect on the antiretroviral activity of GS-9148. Viruses carrying four or more thymidine analog mutations showed a substantially smaller change in GS-9148 activity relative to that observed with most marketed NRTIs. GS-9131, an ethylalaninyl phosphonoamidate prodrug designed to maximize the intracellular delivery of GS-9148, is a potent inhibitor of multiple subtypes of HIV-1 clinical isolates, with a mean 50% effective concentration of 37 nM. Inside cells, GS-9131 is readily hydrolyzed to GS-9148, which is further phosphorylated to its active diphosphate metabolite (A. S. Ray, J. E. Vela, C. G. Boojamra, L. Zhang, H. Hui, C. Callebaut, K. Stray, K.-Y. Lin, Y. Gao, R. L. Mackman, and T. Cihlar, Antimicrob. Agents Chemother. 52:648-654, 2008). GS-9148 diphosphate acts as a competitive inhibitor of RT with respect to dATP (Ki = 0.8 µM) and exhibits low inhibitory potency against host polymerases including DNA polymerase {gamma}. Oral administration of GS-9131 to beagle dogs at a dose of 3 mg/kg of body weight resulted in high and persistent levels of GS-9148 diphosphate in peripheral blood mononuclear cells (with a maximum intracellular concentration of >9 µM and a half-life of >24 h). This favorable preclinical profile makes GS-9131 an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.
INTRODUCTION
Therapeutic regimens containing nucleoside and nucleotide reverse transcriptase (RT) inhibitors (NRTIs) in combination with other antiretrovirals represent the current standard of care for the treatment of the majority of both therapy-na•ve and therapy-experienced human immunodeficiency virus (HIV)-infected patients (10). However, the extremely effective evolution of HIV may frequently lead to the development of resistance to antiretrovirals, including NRTIs, thereby diminishing their long-term clinical benefit. In addition, cross-resistance among multiple NRTIs due to specific mutations in RT limits the treatment options available for individuals for whom current therapies have failed (11, 46). The prevalence of NRTI resistance mutations among HIV-infected individuals with persistent viremia is estimated to be as high as 70% (35, 40, 43), and an increasing rate of the transmission of drug-resistant HIV variants has been observed among newly infected patients (13). The success of chronic therapy with some of the current NRTIs may also be affected by various adverse symptoms including hepatotoxicity, pancreatitis, neuropathy, peripheral lipoatrophy, and lactic acidosis (4, 5, 31, 32). Some of these toxicities are likely to be related to the effects that NRTIs have on mitochondria due to the ability of the active metabolites to interfere with the replication of mitochondrial DNA (mtDNA) (18, 47). Therefore, a significant need remains for novel NRTIs with favorable resistance profiles, improved safety, long-term tolerability, and the potential for once-daily dosing to facilitate patient compliance.
Multiple novel antiretroviral nucleoside analogs have recently been evaluated, both preclinically and clinically, for the treatment of patients with HIV NRTI resistance (1, 12, 21, 22, 33, 34, 42), but only a few have progressed toward late-stage clinical development. We elected to explore nucleoside phosphonates (nucleotide analogs) as they offer a unique pharmacological properties including long intracellular half-lives (15), efficient activation in both dividing and nondividing lymphoid cells (41), and the opportunity to apply prodrug strategies to optimize in vivo pharmacokinetics and tissue distribution (26). Previously, the design of a wide range of acyclic nucleoside phosphonates yielded a number of promising antivirals (9, 16), culminating in the clinical approval of adefovir dipivoxil and tenofovir disoproxil for the treatment of hepatitis B and HIV infections, respectively. In contrast, comparatively fewer cyclic ribose-modified nucleoside phosphonates with antiviral activities have been identified. Among these, recent examples are nucleotides containing a 2'-deoxythreose sugar moiety (50). Independently, 2',3'-didehydro-2',3'-dideoxyribose phosphonates have been explored in the past, with the prototype adenine derivative 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine (d4AP) identified as a potent antiretroviral inhibitor (20). We subsequently observed that d4AP maintains its potent activity against viruses with major NRTI resistance mutations. To minimize the undesirable mitochondrial toxicity associated with d4AP, its 2'-fluorine analog GS-9148 {[5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl] phosphonic acid} (Fig. 1) was prepared. Here we report on the favorable biological profile of GS-9148 and its orally bioavailable phosphonoamidate prodrug GS-9131 {9-(R)-4'-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxyphosphonyl]methoxy]-2'-fluoro-1'-furanylad-enine} (Fig. 1).
The design of novel nucleotide analogs and their prodrugs described in the present study was motivated primarily by the need for new agents that exhibit clinical efficacy for HIV-infected patients with NRTI resistance. Because of the extensive existing experimental and clinical experience with the NRTI class, broad in vitro and in vivo profiling of new candidate molecules are required, with a special emphasis on minimizing class-specific toxicity, maintaining activity against a broad spectrum of NRTI-resistant viruses, and achieving high intracellular levels of the active metabolite in target cells in vivo. Based on these and other criteria, a novel nucleotide, GS-9148, and its phosphonoamidate prodrug GS-9131 were selected as candidates for development.
Activity of GS-9148 against NRTI-resistant HIV-1 variants.
Characterization of the resistance profile of GS-9148 in comparison with the approved NRTIs was carried out using a PhenoSense assay. All inhibitors were tested in parallel against 18 patient-derived HIV-1 recombinant strains containing various combinations of all major known NRTI resistance-associated mutations.Viruses carrying the K65R, K70E, L74V, or M184V mutation, as well as various combinations thereof, were fully susceptible or slightly hypersensitive to GS-9148, responses that were similar to those of AZT and unlike that of most of the other marketed NRTIs (Fig. 4 and see supplemental material). Furthermore, while most viruses with thymidine analog mutations (TAMs) showed substantial cross-resistance to all of the marketed NRTIs that were tested, GS-9148 retained its activity against viruses with four or more TAMs, including combinations containing the M41L and L210W mutations (Fig. 4 and see supplemental material).
A direct comparison between GS-9148 and tenofovir revealed statistically significant differences in the degrees of their resistance among K65R-containing isolates (mean changes of 0.8-fold and 2.1-fold for GS-9148 and tenofovir, respectively; n = 6; P < 0.003) and TAM-containing isolates (mean changes of 1.2-fold and 4.3-fold for GS-9148 and tenofovir, respectively; n = 7; P < 0.02). In addition, unlike any of the marketed NRTIs that were tested, GS-9148 showed a minimal loss of activity against a multidrug-resistant virus containing TAMs in combination with M184V and an insertion at T69. The only virus from the tested set of mutants displaying more than twofold reduced susceptibility to GS-9148 contained the Q151M multi-NRTI resistance complex. However, this virus also showed considerable resistance to all approved NRTIs except tenofovir. Collectively, these data indicate that among the NRTIs tested, GS-9148 is the only inhibitor exhibiting uncompromised activity against the K65R, L74V, and M184V mutation-carrying viruses, combined with minimal resistance due to multiple TAMs
FIG. 4. (A) Comparison of the resistance profile of GS-9148 with those of clinically approved NRTIs. The bars represent the change in the susceptibility of each mutant virus relative to that of the wild-type control strain, using a PhenoSense assay (Monogram Biosciences). GS-9148 (green), TFV (yellow), d4T (red), FTC (light blue), ddI (orange), ABC (purple), AZT (dark blue). To improve the resolution of lower resistance, a greater than 30-fold change is not depicted. The exact values of each virus' resistance to the NRTIs tested are provided in the supplemental material. (B) List of HIV-1 strains used for the resistance analysis, with primary resistance mutations present in RT.
DISCUSSION
The design of novel nucleotide analogs and their prodrugs described in the present study was motivated primarily by the need for new agents that exhibit clinical efficacy for HIV-infected patients with NRTI resistance. Because of the extensive existing experimental and clinical experience with the NRTI class, broad in vitro and in vivo profiling of new candidate molecules are required, with a special emphasis on minimizing class-specific toxicity, maintaining activity against a broad spectrum of NRTI-resistant viruses, and achieving high intracellular levels of the active metabolite in target cells in vivo. Based on these and other criteria, a novel nucleotide, GS-9148, and its phosphonoamidate prodrug GS-9131 were selected as candidates for development.
The discovery of the favorable resistance profile of the previously described nucleoside phosphonate d4AP (20) was an important initial step toward the design of GS-9148. However, the mitochondrial toxicity observed with d4AP precluded considering it for further development. The toxicity of d4AP was not completely unexpected given the potent inhibition of DNA polymerase {gamma} by its DP metabolite (6). Multiple rational approaches have been taken to address this limitation. Among the modifications of d4AP that have been explored, only the 2'-fluorine substitution resulted in both the elimination of effects on mtDNA and the retention of potency and favorable resistance profile, leading to the selection of GS-9148. The precedent for this modification was originally established with 2'-ß-fluoro-2',3'-dideoxyadenosine, which showed a markedly reduced effect on mtDNA compared to that of the unsubstituted 2',3'-dideoxyadenosine. This can be explained by substantial differences in the affinity levels of the corresponding active TPs for DNA polymerase {gamma} (44). Similarly, the 2'-fluorine substitution on the d4AP scaffold leads to a marked reduction in the inhibition of DNA polymerase {gamma} by the corresponding DP metabolite (38). Although 2'-fluoro-2',3'-didehydro-2',3'-dideoxyadenosine (the corresponding nucleoside analog of GS-9148) was prepared previously and its potent in vitro antiretroviral activity has been demonstrated (25), its potential for mitochondrial toxicity has not been studied in detail. Hence, at present, it is not clear whether the phosphonate in the context of 2'-fluorine substitution offers additional benefit with respect to a reduction in the mitochondrial toxicity potential.
Results from a PhenoSense analysis indicate that GS-9148 meets the target resistance profile set for the development candidate by maintaining its activity against multiple patient-derived HIV strains with the major known NRTI resistance mutations. Importantly, its profile appears to be distinct from that of the clinically approved NRTIs in that GS-9148 was the only inhibitor tested that showed no reduction in potency due to K65R, L74V, and M184V mutations, together with the minimal resistance associated with multiple TAMs. Recently, we have also shown that GS-9148 selects for the rare K70E primary resistance mutation in RT (8). In vitro exposure to increasing concentrations of GS-9148 for 7 months resulted in the emergence of an HIV-1 variant with the K70E, D123N, and T165I mutations in RT and an approximately threefold reduced susceptibility to GS-9148. A search of the Stanford HIV drug resistance database (http://hivdb.stanford.edu/) indicated that the K70E mutation is present only in NRTI-experienced patients at a frequency of less than 0.5% of database samples, which sharply contrasts with the much higher incidence of other NRTI resistance mutations such as M184V (>45% of database samples) and various TAMs (10 to 35% of database samples).
Effective oral administration and intracellular delivery of GS-9148 require the use of lipophilic prodrug moieties to mask the negative charges present on the phosphonate group at a physiological pH level. Based on the favorable pharmacokinetic profile and tissue distribution pattern demonstrated with phosphonoamidate prodrugs of tenofovir (26), we decided to explore a similar strategy with GS-9148 rather than rely on the diester prodrug concept employed in the prior design of tenofovir disoproxil or adefovir dipivoxil (9). Among multiple characterized phosphonoamidates, GS-9131 was selected as the optimal prodrug of GS-9148. GS-9131 is a potent inhibitor of in vitro HIV-1 replication, both in established T-cell lines and in various primary cells, including macrophages. In activated human PBMCs, GS-9131 inhibits replication in multiple subtypes of HIV-1 clinical isolates with a 4- to 10-fold higher potency than that of AZT. At the same time, GS-9131 has good in vitro selectivity in several human cell types, including renal proximal tubule cells, the target for dose-limiting clinical adverse effects of some nucleoside phosphonates (7, 23, 24).
Inside lymphoid cells, GS-9131 is readily hydrolyzed to the parent nucleotide GS-9148, which undergoes effective phosphorylation to the active DP metabolite (39). In vitro metabolism studies demonstrated that a GS-9131 concentration approximately 100-fold lower than GS-9148 is required to achieve similar intracellular levels of GS-9148-DP, a result consistent with a marked enhancement of cellular permeation of GS-9148 by its conversion to GS-9131 (39). Once formed, GS-9148-DP is effectively retained in cells (39) and acts as a competitive inhibitor of HIV-1 RT with respect to the natural substrate dATP. Additional mechanistic enzymology studies have demonstrated the ability of GS-9148 to function as a chain terminator following its incorporation into DNA by RT (48).
When GS-9131 was administered to dogs, it exhibited an oral bioavailability of more than 20% as an intact prodrug. The comparison of GS-9148 levels in plasma following oral and i.v. administration of GS-9131 demonstrated an oral bioavailability of more than 60% as the parent GS-9148, indicating effective intestinal absorption. This is likely a consequence of the well-balanced properties of GS-9131, including its lipophilicity, solubility, and stability in the gastrointestinal tract. In addition, GS-9131 exhibits good stability in both dog and human plasma, with a t1/2 of 1 h, but undergoes fast hydrolysis in lymphoid cells and cellular extracts (3, 39). This profile is in contrast with that of diester nucleotide prodrugs such as tenofovir disoproxil, which displays limited stability in plasma (t1/2 < 1 min) and no selectivity of intracellular activation over systemic hydrolysis (26). Thus, GS-9131 acts in vivo as an intracellular prodrug that allows for the effective delivery of GS-9148 and its metabolites into PBMCs. In this context and somewhat similar to other NRTIs, the intracellular level of GS-9148-DP in target cells rather than the plasma level of parent GS-9148 should be taken into account as a predictor for the antiretroviral activity of GS-9131 in a clinical setting. Following the oral administration of GS-9131 to dogs at 3 mg/kg, the concentration of GS-9148-DP in PBMCs approached 10 µM, a level approximately 20-fold higher than that of the tenofovir DP detected in PBMCs of patients treated with tenofovir disoproxil fumarate at the standard clinical dose of 300 mg (15). As discussed in further detail in the report by Ray et al., these intracellular levels of GS-9148-DP are expected to result in an antiretroviral effect in patients (39). In addition, prolonged in vivo intracellular retention of GS-9148-DP suggests the possibility for once-daily dosing, an important aspect for facilitating the compliance of patients. Finally, both the antiviral combination experiments described here and the in vitro metabolic drug-drug interaction studies described by Ray et al. (39) suggest that GS-9131 should be suitable for use in combination with multiple antiretrovirals including other NRTIs.
Results from the present in vitro and in vivo pharmacological profiling and from additional preclinical evaluations indicate that the nucleotide prodrug GS-9131 is an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.
RESULTS
Rational design of GS-9148. As a part of our search for novel NRTIs with favorable biological profiles, a structurally diverse set of both acyclic and ribose-modified nucleoside phosphonate analogs were evaluated with various in vitro assays that characterize anti-HIV-1 activity, cytotoxicity, and resistance profiles against viruses carrying major NRTI resistance mutations. The previously described nucleoside phosphonate analog d4AP (Fig. 2, compound 1) (20) was identified as a potent inhibitor of both wild-type and NRTI-resistant HIV-1 strains (Table 1). However, d4AP interfered strongly with the replication of mtDNA (Table 1), and so it was precluded from further consideration for clinical development. Related 2',3'-dideoxyribose and 2'3'-didehydro-2',3'-dideoxyribose analogs with different nucleobases were evaluated in parallel, but despite somewhat reduced effects on mtDNA replication, these analogs had inferior resistance profiles (29). Since isomeric L-nucleosides (e.g., 3TC) and carbocyclic nucleosides (e.g., ABC) are known to exhibit minimal effects on mtDNA replication (2), we sought to utilize similar approaches to reduce the toxicity of d4AP. Although the L-isomer of d4AP (L-d4AP; Fig. 2, compound 2) had good potency and abrogated the mitochondrial toxicity, its resistance profile was inferior to those of both d4AP and several approved NRTIs. The previously reported carbocyclic analog of d4AP (Cd4AP; Fig. 2, compound 3) (19) showed only marginal antiretroviral activity in comparison with that of d4AP. Finally, a third approach to reduce mitochondrial toxicity of d4AP, based on structural differences in the active site domain of RT (17) and mtDNA polymerase {gamma} (14) interacting with the substrate 2'-deoxyribose region, was initiated. In this context, prior studies have demonstrated that 2'-fluoro-2',3'-dideoxynucleosides exhibit reduced mitochondrial toxicity compared to that of corresponding 2'-unsubstituted compounds (44). The analogous modification of d4AP resulted in 2'-fluoro-d4AP (Fd4AP, GS-9148; Fig. 2, compound 4), which exhibited both sufficient antiretroviral activity and a favorable resistance profile against viral strains containing major NRTI mutations (Table 1). Importantly, the introduction of 2'-fluorine into the ribose ring of d4AP eliminated its effect on mtDNA (Table 1). As demonstrated by further analyses using both DNA hybridization and real-time PCR, the treatment of HepG2 cells for up to 21 days with 50 to 300 µM GS-9148 did not produce any measurable reduction of mtDNA, which contrasted with some of the approved NRTIs such as ddI, d4T, and ddC that reduced the content of mtDNA by 70 to 90% under the same conditions (data not shown). Based on these results, additional 2'-fluoro-2',3'-didehydro-2',3'-dideoxy nucleoside phosphonates with guanine (Fd4GP), hypoxanthine (Fd4IP), and 2,6-diaminopurine (Fd4DAPP) bases (Fig. 2, compounds 5 to 7) were synthesized and characterized. Among these analogs, only Fd4GP was active against HIV-1 but was overall less attractive because of its reduced selectivity (i.e., the ratio of CC50 to EC50) in MT-2 cells compared to GS-9148.
Selection of GS-9131 as an optimal prodrug of GS-9148.
The cellular permeation of nucleotides is limited by their negative charge at a physiological pH level, which requires the use of lipophilic prodrugs for their in vivo oral administration. Recently described phosphonoamidates of tenofovir improve the oral bioavailability of the parent nucleotide and allow for its effective in vivo delivery into target lymphoid cells and tissues (26). Hence, a series of phosphonoamidate prodrugs of GS-9148 with various amino acid residues and ester moieties were prepared and characterized for their antiviral activity, cytotoxicity, and in vivo delivery of GS-9148 metabolites into PBMCs following administration to dogs. Both mono-phenol mono-phosphonoamidates and bis-phosphonoamidates substantially enhanced the antiretroviral potency of GS-9148 while they maintained favorable selectivity in MT-2 cells. Consistent with the increase in the cellular permeation of GS-9148, prodrugs with the highest lipophilicity such as mono(isobutyl-phenylalanine) amidate (Fig. 3, compound 12) and bis(n-butyl-alanine) amidate (Fig. 3, compound 13) were more than 1,000- and 250-fold more active, respectively, than GS-9148 by itself (Table 2). In comparison, mono(ethyl-alanine) amidate (Fig. 3, compound 8) improved the activity of GS-9148 by approximately 50-fold, whereas the mono(isopropyl-alanine) prodrug (Fig. 3, compound 11) was only poorly active relative to that of other prodrugs of GS-9148. Despite its potent in vitro activity, bis-amidate (Fig. 3, compound 13) was quite ineffective in delivering GS-9148 metabolites into PBMCs following i.v. administration to dogs, producing only approximately threefold higher intracellular levels of GS-9148 metabolites compared to that from the same dose of GS-9148 by itself (Table 2). This is likely a consequence of the extensive metabolic clearance of this compound. In contrast, monoamidate prodrugs (Fig. 3, compounds 8 and 12) administered i.v. enhanced the in vivo intracellular delivery of GS-9148 metabolites by 57- and 106-fold, respectively, relative to that of GS-9148 by itself. However, in comparison with what was seen with compound 12, the oral administration of compound 8 to dogs resulted in fourfold higher levels of GS-9148 metabolites in PBMCs. Therefore, the two diastereomers of mono(ethyl-alanine) prodrug were separated and further characterized. Diastereomer A, designated GS-9131 (Fig. 3, compound 9), showed twofold more potent antiretroviral activity in MT-2 cells and produced threefold higher levels of GS-9148 metabolites in PBMCs from orally dosed dogs than the diastereomer B (Fig. 3, compound 10). Based on this profile, GS-9131 was selected for further evaluation.
Characterization of antiretroviral activities of GS-9131 and GS-9148.
GS-9131 is substantially more potent in activated PBMCs (EC50 = 3.7 nM; Table 3) than in MT-2 cells (EC50 = 150 nM; Table 2), whereas GS-9148 showed levels of antiviral potency that were similar in both cell types, indicating that the improvement in GS-9131 activity in PBMCs is likely due to its enhanced cellular permeation and/or more effective intracellular hydrolysis. GS-9131 is also a potent HIV-1 inhibitor in a single-cycle infection assay with primary CD4+ T lymphocytes (Table 3). Furthermore, both GS-9148 and GS-9131 inhibit HIV-1 in primary macrophages.
GS-9148 and GS-9131 maintain consistent levels of activity across multiple HIV-1 clinical isolates of different subtypes, with 4- to 10-fold higher potency for GS-9131 than for AZT (Table 4). Differences between the activity of GS-9131 against clinical isolates and against the laboratory BaL strain are likely due to different conditions for both assays, as described in Materials and Methods. Both GS-9148 and GS-9131 are also active in MT-2 cells against multiple isolates of HIV-2, with mean EC50s of 14 and 0.36 µM, respectively (Table 5). Importantly, GS-9131 exhibits a minimal approximately 1.7-fold increase in its EC50 against HIV-1 in the presence of 50% human serum. When GS-9131 was tested in parallel with the HIV protease inhibitor nelfinavir, the potency of the protease inhibitor was reduced by more than 28-fold by the addition of 50% human serum (data not shown).
Activity in combination with other antiretrovirals.
The activity of GS-9148 in combination with multiple approved antiretrovirals was assessed by using a cytopathic assay with HIV-1-infected MT-2 cells. Results indicated a high level of synergy in the activity of GS-9148 in combination with AZT, ABC, or efavirenz (Table 6). Moderate synergy was found for combinations of GS-9148 with FTC or lopinavir, and the combination of GS-9148 with tenofovir showed an additive to slightly synergistic antiviral effect. Since GS-9148 and tenofovir are both adenine nucleotide analogs, their combination was further characterized mechanistically by using the RT enzyme inhibition assay. In accordance with the antiviral drug combination studies, an additive inhibitory effect was detected with combinations of the DP metabolites of GS-9148 and tenofovir (data not shown). In addition, no in vitro intracellular metabolic drug-drug interactions between GS-9148 and tenofovir or their prodrugs were detected in PBMCs treated with supratherapeutic concentrations of these compounds (39).
Cytotoxicity in liver and renal cells.
In addition to MT-2 cells (Tables 1 and 2), the in vitro cytotoxicity levels of GS-9148 and GS-9131 were tested in a human liver cell line (HepG2) and in RPTECs. Both GS-9148 and GS-9131 exhibited low levels of cytotoxicity in HepG2 cells and in RPTECs from two separate donors, with CC50s above 2,000 and 50 µM for both cell types, respectively (Table 7). In comparison, tenofovir and GS-7340, a tenofovir prodrug from the same class as GS-9131, had CC50s of 1,530 and 6.9 µM, respectively, in HepG2 cells. The acyclic nucleotide analog cidofovir, known to cause renal tubular dysfunction (24), was significantly cytotoxic in RPTECs from both donors. GS-9148 was also substantially less cytotoxic than cidofovir in CHO cells stably expressing functional renal transporter hOAT1 (Table 7). We have confirmed that this last difference is due to the weaker affinity of hOAT1 for GS-9148 than for cidofovir (data not shown), suggesting a less effective renal transport and possibly a lower potential for nephrotoxicity than that of acyclic nucleotide analogs. Finally, quantitative studies confirmed that despite increased cellular permeation, GS-9131 at concentrations of up to 50 µM did not cause any selective depletion of mtDNA in HepG2 cells (data not shown), an observation consistent with the low potential of GS-9148 to interfere with the replication of mtDNA.
Inhibition of HIV-1 RT and host DNA polymerases.
In vitro metabolism experiments demonstrated effective intracellular conversion of GS-9131 to the active metabolite GS-9148-DP in various lymphoid cells (39). In steady-state enzyme kinetic experiments, GS-9148-DP acts as a competitive inhibitor of HIV-1 RT with respect to dATP, exhibiting a level of potency comparable to that of the active metabolites of 3TC and FTC (Table 8).
Pharmacokinetic profile of GS-9131 administered orally to dogs.
As illustrated in Fig. 5, after GS-9131 was given orally to male beagle dogs at 3 mg/kg, it was rapidly absorbed, generating a maximum serum drug concentration (Cmax) of 2.5 µM, and was subsequently eliminated from plasma with an apparent terminal half-life (t1/2) of less than 20 min. As determined following i.v. administration, the systemic clearance of GS-9131 was approximately 1.4 liters/h/kg. Combined i.v. and oral data for GS-9131 indicate a mean oral bioavailability of 26%. Concomitant with the elimination of GS-9131 from plasma, GS-9148 was observed to reach a Cmax of 1.1 µM within approximately 2 h after dosing. A comparison of the exposure to GS-9148 following i.v. and oral administration suggests that the majority of the oral dose (>60%) is absorbed from the gastrointestinal tract.
The short plasma exposure to GS-9131 following its oral administration to dogs was sufficient to effectively deliver high levels of GS-9148 and its DP into PBMCs. Analysis of cellular extracts from isolated PBMCs demonstrated rapid intracellular accumulation of GS-9148 (Fig. 5), with its intracellular decay mirroring the increase in the levels of GS-9148-DP. These results indicate that GS-9148 undergoes effective intracellular phosphorylation in PBMCs in vivo. Notably, GS-9148-DP reached a peak concentration of more than 9 µM in PBMCs, which persisted for more than 24 h after dosing. Together, these data indicate that GS-9131 administered orally to dogs delivers high and persistent intracellular levels of the active metabolite GS-9148-DP to PBMCs.
|
|
| |
| |
|
|
|
